<DOC>
	<DOCNO>NCT00343382</DOCNO>
	<brief_summary>RATIONALE : Pilocarpine may decrease vaginal dryness improve quality life patient breast cancer It yet know whether pilocarpine effective placebo treat vaginal dryness patient breast cancer . PURPOSE : This randomized phase III trial study pilocarpine see well work compare placebo treat vaginal dryness patient breast cancer .</brief_summary>
	<brief_title>Pilocarpine Treating Vaginal Dryness Patients With Breast Cancer</brief_title>
	<detailed_description>OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord age ( 18 45 v 46 55 v 56 65 v &gt; 65 ) , concurrent tamoxifen therapy ( yes v v unknown [ e.g. , blind clinical study ] ) , concurrent aromatase inhibitor therapy ( yes v v unknown [ e.g. , blind clinical study ] ) , perception severity vaginal symptom baseline ( mild v moderate v severe ) . Patients randomize 1 4 treatment arm . The primary secondary objective study describe . OBJECTIVES : Primary - Determine effectiveness pilocarpine hydrochloride alleviation vaginal dryness patient breast cancer . Secondary - Evaluate toxicity arise pilocarpine hydrochloride patient . - Evaluate quality life patient treat pilocarpine hydrochloride . Quality life assess baseline weekly 6 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>Required Characteristics : 1 . Adult post menopausal woman woman childbearing potential ( ≥ 18 year ) history breast cancer ( currently evidence disease ) woman want take vaginal estrogen fear increase risk breast cancer . Postmenopausal status determine primary physician . 2 . Significant vaginal complaint define persistent vaginal dryness and/or itch sufficient severity make patient desire therapeutic intervention . Symptoms present ≥ 2 month prior randomization . 3 . Life expectancy &gt; 6 month 4 . Ability complete questionnaire ( ) assistance . Contraindications : 1 . Initiation discontinuation tamoxifen aromatase inhibitor ≤2 month prior randomization plan initiate discontinue medication 6week study . 2 . Active vaginal infection 3 . Concurrent chemotherapy 4 . Acute iritis 5 . Current past use pilocarpine ( regardless purpose ) 6 . Planned use vaginal preparation study period ( include counter herbal preparation ) . Note : Lubricants use sexual intercourse permit . 7 . Use vaginal preparation ≤ 1 week prior study entry ( Exception : If patient use vaginal preparation previous week stop , place study plan start pretreatment questionnaire one week later ) . Note : Lubricants use sexual intercourse permit . 8 . Current ( ≤ 4weeks prior randomization ) , plan study period , use estrogen product . 9 . A diagnosis asthma , COPD , CAD narrow angle glaucoma , know cholelithiasis . 10 . Hepatic renal insufficiency define history elevation SGOT ≥1.5 x ULN creatinine ≥ 1.5 x ULN within past year . 11 . Concurrent use anticholinergic 12 . Use pharmacologic soy preparation 13 . Known history cardiac arrhythmia . ( Patients occasional PVC 's PAC 's require treatment eligible . ) 14 . Prior concurrent pelvic radiation therapy 15 . Prior radical pelvic surgery ( TAH/BSO allow ) 16 . Use beta adrenergic antagonist 17 . Diagnosis follow condition : Vulvar vaginal dysplasia Essential vulvodynia Vulvar vestibulitis Vaginal prolapse Bartholin cyst/abscess History Bartholin gland surgery Lichen sclerosis Lichen planus vulvovaginal region Desquamative vaginitis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>sexuality reproductive issue</keyword>
	<keyword>sexual dysfunction</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>